187 related articles for article (PubMed ID: 20077251)
1. Statistical methods for assessment of biosimilarity using biomarker data.
Chow SC; Lu Q; Tse SK; Chi E
J Biopharm Stat; 2010 Jan; 20(1):90-105. PubMed ID: 20077251
[TBL] [Abstract][Full Text] [Related]
2. A comparison of moment-based and probability-based criteria for assessment of follow-on biologics.
Chow SC; Hsieh TC; Chi E; Yang J
J Biopharm Stat; 2010 Jan; 20(1):31-45. PubMed ID: 20077247
[TBL] [Abstract][Full Text] [Related]
3. Statistical test for evaluation of biosimilarity in variability of follow-on biologics.
Hsieh TC; Chow SC; Liu JP; Hsiao CF; Chi E
J Biopharm Stat; 2010 Jan; 20(1):75-89. PubMed ID: 20077250
[TBL] [Abstract][Full Text] [Related]
4. Statistical assessment of biosimilar products.
Chow SC; Liu JP
J Biopharm Stat; 2010 Jan; 20(1):10-30. PubMed ID: 20077246
[TBL] [Abstract][Full Text] [Related]
5. Assessing bioequivalence using genomic data.
Chow SC; Shao J; Li L
J Biopharm Stat; 2004 Nov; 14(4):869-80. PubMed ID: 15587969
[TBL] [Abstract][Full Text] [Related]
6. Comparability and biosimilarity: considerations for the healthcare provider.
Lee JF; Litten JB; Grampp G
Curr Med Res Opin; 2012 Jun; 28(6):1053-8. PubMed ID: 22519391
[TBL] [Abstract][Full Text] [Related]
7. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration.
Davit BM; Nwakama PE; Buehler GJ; Conner DP; Haidar SH; Patel DT; Yang Y; Yu LX; Woodcock J
Ann Pharmacother; 2009 Oct; 43(10):1583-97. PubMed ID: 19776300
[TBL] [Abstract][Full Text] [Related]
8. Frequency estimator for assessing of follow-on biologics.
Lu Y; Zhang ZZ; Chow SC
J Biopharm Stat; 2014; 24(6):1280-97. PubMed ID: 25072640
[TBL] [Abstract][Full Text] [Related]
9. Scientific considerations for assessing biosimilar products.
Chow SC; Wang J; Endrenyi L; Lachenbruch PA
Stat Med; 2013 Feb; 32(3):370-81. PubMed ID: 22933240
[TBL] [Abstract][Full Text] [Related]
10. The evaluation of biosimilarity index based on reproducibility probability for assessing follow-on biologics.
Hsieh TC; Chow SC; Yang LY; Chi E
Stat Med; 2013 Feb; 32(3):406-14. PubMed ID: 22899403
[TBL] [Abstract][Full Text] [Related]
11. Nonparametric tests for evaluation of biosimilarity in variability of follow-on biologics.
Zhang N; Yang J; Chow SC; Chi E
J Biopharm Stat; 2014; 24(6):1239-53. PubMed ID: 25036940
[TBL] [Abstract][Full Text] [Related]
12. Supplemental applications proposing labeling changes for approved drugs, biologics, and medical devices. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2008 Aug; 73(164):49603-10. PubMed ID: 18958946
[TBL] [Abstract][Full Text] [Related]
13. The scope and requirements related to preclinical and clinical studies of a new medicinal product, including biotechnological and biosimilar products.
Brodniewicz-Proba T
Acta Pol Pharm; 2008; 65(6):641-5. PubMed ID: 19172845
[TBL] [Abstract][Full Text] [Related]
14. Requirements for submission of bioequivalence data; final rule. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2009 Jan; 74(11):2849-62. PubMed ID: 19385107
[TBL] [Abstract][Full Text] [Related]
15. Statistical assessment of biosimilarity based on relative distance between follow-on biologics.
Kang SH; Chow SC
Stat Med; 2013 Feb; 32(3):382-92. PubMed ID: 22941672
[TBL] [Abstract][Full Text] [Related]
16. United States Food and Drug Administration requirements for approval of generic drug products.
Meyer MC
J Clin Psychiatry; 2001; 62 Suppl 5():4-9; discussion 23-4. PubMed ID: 11305846
[TBL] [Abstract][Full Text] [Related]
17. New drug, antibiotic, and biological drug product regulations; accelerated approval--FDA. Final rule.
Fed Regist; 1992 Dec; 57(239):58942-60. PubMed ID: 10123232
[TBL] [Abstract][Full Text] [Related]
18. Lessons learned from independent central review.
Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
[TBL] [Abstract][Full Text] [Related]
19. An overview of the FDA publication Approved Drug Products with Therapeutic Equivalence Evaluations.
Knoben JE; Scott GR; Tonelli RJ
Am J Hosp Pharm; 1990 Dec; 47(12):2696-700. PubMed ID: 2278285
[TBL] [Abstract][Full Text] [Related]
20. Evaluating statistical methods to establish clinical similarity of two biologics.
Lei L; Olson K
J Biopharm Stat; 2010 Jan; 20(1):62-74. PubMed ID: 20077249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
